DMAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DiaMedica Therapeutics Inc (DMAC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no clear trading signals from Intellectia Proprietary Trading Signals. While the technical analysis shows some neutral to slightly positive indicators, the overall sentiment and lack of growth prospects suggest holding off on investing in this stock for now.
The MACD histogram is positive at 0.0557, indicating slight bullish momentum. RSI is neutral at 58.103, suggesting no clear overbought or oversold conditions. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5), signaling a downward trend. Key resistance is at 6.779 and support at 5.885.
The MACD histogram is positive, and there is a 60% chance of a slight price increase in the next week (3.83%).
No recent news, no significant hedge fund or insider trading trends, and weak financial performance with negative net income and EPS decline. The stock also lacks any recent trading signals from Intellectia Proprietary Trading Signals.
In Q4 2025, revenue remained at 0 with no growth. Net income improved slightly by 10.63% YoY but remains negative at -$8.74M. EPS dropped by -5.56% YoY to -0.17, showing continued losses. Gross margin remains at 0, indicating no profitability.
No recent analyst rating or price target changes available.
